Interleukin-15 (IL-15) is a key signaling protein in the intricate orchestra that is the human immune response. IL-15’s relevance spans from its role in diseases like cancer and autoimmunity to its application in cell therapy enhancement. Its versatile functions—ranging from bolstering T cell survival to fine-tuning immune reactions—hold tremendous therapeutic potential.
Interleukin-15 is a pivotal cytokine in the immune system, belonging to the same common cytokine receptor γ-chain (γc) family as IL-2 and IL-7. IL-15 plays a crucial role in enhancing the survival, proliferation, and activation of various immune cells, particularly memory CD8+ T cells and natural killer (NK) cells.
IL-15 binds to a receptor complex on these cells, initiating intricate signaling pathways that bolster immune responses against infections and malignancies. Its ability to stimulate long-lasting immunity and promote the expansion of potent effector cells makes IL-15 a key regulator in immune surveillance and a promising target for innovative therapeutic interventions.
IL-15 expression occurs in a wide array of tissues, emphasizing its importance in the body’s immune response. Beyond traditional immune system cell sources, such as monocytes, macrophages, and dendritic cells (DCs), Anderson et al. discovered in 1995 that non-immune cells like skeletal muscle and epithelial cells also produce IL-15. This decentralized expression pattern underscores IL-15’s role in shaping a targeted immune response at various tissue sites.
As a member of the same family, IL-15 shares common gamma (γ) chain receptor subunits with IL-2 and IL-7, creating overlapping signaling pathways. Similar to IL-2 and IL-7, IL-15 is synthesized in response to stimuli like infections or inflammation. Unlike IL-2, which is produced predominantly by activated CD4+ T cells, IL-15 has a broader cellular source, contributing to its unique immunomodulatory properties.
IL-15 binds to a heterotrimeric receptor complex consisting of IL-15 receptor alpha (IL-15Rα), IL-2Rβ, and γ-chain, as detailed by Giri et al. in their study examining the overlap of IL-2’s receptor.
This distinctive receptor configuration plays a pivotal role in the trans-presentation of IL-15 to other cells, including T cells and NK cells, enhancing their survival, proliferation, and effector functions. This feature has also spurred interest in utilizing IL-15 to bolster the efficacy of cell-based therapies, particularly chimeric antigen receptor T cell (CAR-T) therapy.
IL-15’s effects on T cells and NK cells are multifaceted. It serves as a master regulator of T cell and NK cell proliferation, playing a pivotal role in shaping the immune response.
Through its dynamic signaling pathways, IL-15 stimulates the expansion of memory CD8+ T cells, which is crucial for establishing long-term immunity against pathogens and tumors. It fuels the survival, division, and functionality of these memory CD8+ T cells, equipping the immune system with a potent arsenal poised to respond to future encounters.
Additionally, IL-15 propels the proliferation of NK cells, innate immune sentinels that swiftly recognize and eliminate infected or transformed cells. By fostering the expansion of both T cells and NK cells, IL-15 establishes a harmonious interplay between the immune system’s adaptive and innate roles, culminating in a robust and comprehensive defense mechanism against diverse challenges.
IL-15’s involvement in immune responses against infections, cancers, and autoimmune disorders underscores its potential therapeutic applications. In addition to T cells, IL-15 enhances the cytotoxic activity of NK cells against cancerous tumor cells, as shown in the work of Zhang et al., making it an attractive candidate for cancer immunotherapy. Meanwhile, its capacity to stimulate memory CD8+ T cells can facilitate long-lasting immunity.
Conversely, a study by Yokoyama et al. demonstrated that the dysregulated IL-15 signaling has been linked to autoimmune conditions like celiac disease and rheumatoid arthritis. Harnessing IL-15’s ability to fine-tune immune responses could pave the way for novel treatment strategies.
IL-15 superagonists are engineered forms of IL-15 that exhibit enhanced biological activity compared to native cytokines. These potent molecules not only stimulate the expansion and activation of CD8+ T cells and NK cells but also fine-tune the immune landscape to orchestrate a more robust defense against infections and malignancies.
By modifying IL-15’s structure, studies by researchers like Zhu et al. aim to achieve prolonged signaling, augmented receptor binding, and improved anti-tumor efficacy. These superagonists hold promise in enhancing immune responses for therapeutic purposes. However, they add an increased risk of a runaway immune response, necessitating further investigation to optimize their therapeutic utility.
When incorporated into cell therapy protocols, IL-15 is a powerful stimulant for T cells, promoting their survival, proliferation, and effector functions. During ex vivo cell culture expansion, IL-15 fosters the generation of memory T cells, which retain the ability to recognize and combat previously encountered threats. This characteristic is especially significant in cancer immunotherapy, where the goal is to equip the immune system with long-lasting tools to target and destroy tumor cells.
Cell therapy, including approaches like CAR-T therapy, has shown remarkable success in treating certain cancers. However, limited persistence and insufficient expansion of infused T cells within the patient’s body can hinder the therapy’s efficacy. An important study by Xu et al. showed that IL-15, in combination with IL-7, addresses these challenges by providing the necessary signals to promote the survival and expansion of memory T cells.
By introducing IL-15 during ex vivo T cell expansion, researchers can enhance the generation of CAR-T cells with improved capabilities. These cells exhibit increased persistence, leading to extended therapeutic effects. Additionally, IL-15’s impact on the memory T cell pool ensures the immune system retains a potent anti-tumor memory, ready to respond if the cancer relapses.
Interleukin-15 represents a paradigm shift in the realm of cell therapy. Its ability to enhance T cell survival, proliferation, and function, along with its synergistic potential with other cytokines like IL-7, offers a comprehensive approach to tackling complex diseases like cancer. By integrating IL-15 into cell therapy protocols, researchers are paving the way for more potent and durable treatments that can reshape the landscape of medical interventions.
Nanotein has provided a specific IL-7 & IL-15 CAR-T expansion protocol for use with their best-in-class NanoSparkTM soluble activator technology to facilitate this cutting-edge immunotherapy. This innovative ex vivo approach leverages the potency of IL-15 signaling to enhance the expansion and survival of CAR-T cells in vivo.
By combining IL-15 with NanoSpark™ STEM-T Soluble T Cell Activator during the expansion process, enriched stem cell memory T cells (TSCMs) will persist longer, overcoming limitations associated with traditional CAR-T therapies. The IL-7 & IL-15 CAR-T expansion protocol demonstrates the potential of IL-15 in redefining the landscape of cell-based therapies, offering renewed hope for patients battling challenging diseases.
Have questions? Contact us to learn more.
Best-in-Class solutions for Cell Expansion Reagents